Yes, that's exactly what I'm suggesting.
It was the announcement of that suit against JNJ that helped pump DECN up to .60. The dump is still in process and the mighty, powerful DECN is languishing at .25 and sinking.
It was your word: DECN is no more than a nuisance to JNJ, one of the unpleasant costs of doing business.
JNJ is trading at its all time high, even after having been "beaten" so badly by DECN.
It was the announcement of that suit against JNJ that helped pump DECN up to .60. The dump is still in process and the mighty, powerful DECN is languishing at .25 and sinking.
It was your word: DECN is no more than a nuisance to JNJ, one of the unpleasant costs of doing business.
JNJ is trading at its all time high, even after having been "beaten" so badly by DECN.
Life is as much a merry tavern as it is a sad hotel.
--Tennessee Williams
Recent JNJ News
- Johnson & Johnson introduces VARIPULSE Pro in Europe after CE Mark clearance • IH Market News • 04/07/2026 02:12:35 PM
- Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe • Business Wire • 04/07/2026 12:00:00 PM
- Royalty Pharma signs $500M co-development agreement with J&J • IH Market News • 03/30/2026 12:28:19 PM
- J&J reports one-year ICOTYDE psoriasis trial results show sustained efficacy • IH Market News • 03/30/2026 09:32:48 AM
- ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis • PR Newswire (US) • 03/28/2026 02:00:00 PM
- Nanobiotix Shares Surge After Report of Possible Johnson & Johnson Takeover Interest • IH Market News • 03/25/2026 02:00:48 PM
- Form 13F-HR/A - Quarterly report filed by institutional managers, Holdings: [Amend] • Edgar (US Regulatory) • 03/18/2026 03:57:35 PM
- FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide • PR Newswire (US) • 03/18/2026 11:49:00 AM
- Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer • PR Newswire (US) • 03/13/2026 04:35:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 01:31:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 12:39:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 12:37:30 AM
- Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients • Business Wire • 03/12/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/11/2026 10:17:23 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/11/2026 10:13:23 AM
- Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line • PR Newswire (US) • 03/05/2026 08:55:00 PM
- /C O R R E C T I O N -- Johnson & Johnson/ • PR Newswire (US) • 03/04/2026 12:36:00 AM
- Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE) • PR Newswire (US) • 03/03/2026 01:03:00 PM
- Johnson & Johnson to Host Investor Conference Call on First-Quarter Results • Business Wire • 03/02/2026 09:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/27/2026 07:35:13 PM
- Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer • PR Newswire (US) • 02/26/2026 07:30:00 PM
- Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA) • PR Newswire (US) • 02/24/2026 09:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 10:20:21 PM
